162 results
8-K
EVOK
Evoke Pharma Inc
18 Mar 24
Other Events
5:02pm
. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements
424B3
EVOK
Evoke Pharma Inc
14 Mar 24
Prospectus supplement
6:44pm
Litigation Reform Act of 1995.
This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our … cooperating in expediting the litigation. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its
8-K
EX-99.1
c789n u3nmjwnghen
14 Mar 24
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
4:00pm
8-K
24xjjb6702 ny
14 Feb 24
Unregistered Sales of Equity Securities
9:00am
8-K
5j85r
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
8-K
EX-1.1
rzfb26 lpc5b
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
8-K
EX-99.1
hmmll
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
424B4
e45d795
9 Feb 24
Prospectus supplement with pricing info
5:14pm
8-K
wxx laclfda94xv1
29 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:00am
8-K
m3gzlv1 ttyhd
27 Nov 23
Other Events
4:30pm